A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Beltran, Himisha, Oromendia, Clara, Danila, Daniel C., Montgomery, Bruce, Hoimes, Christopher, Szmulewitz, Russell, Vaishampayan, Ulka, Armstrong, Andrew J., Stein, Mark, Pinski, Jacek, Sailor, Verena, Bareja, Rohan, Romanel, Alessandro, Gumpeni, Naveen, Sboner, Andrea, Dardenne, Etienne, Puca, Loredana, Prandi, Davide, Mosquera, Juan Miguel, Rubin, Mark A., Scher, Howard I., Rickman, David, Demichelis, Francesca, Nanus, David M., Ballman, Karla, Tagawa, Scott T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320304/
https://ncbi.nlm.nih.gov/pubmed/30232224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1912
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados